Evidence map›Paper›PMID 40878891›Full record

ArticleNanomedicine (London, England)2025

Cyclodextrin-AmB-IL-10 antagonist peptide nanoparticles treat leishmaniasis more effectively than conventional AmB.

Ashish Kumar, Ritesh Tiwari, Shobha Kumari, Ravi Ranjan, Vikash Kumar, Sonali Vedika, Kumar Abhishek, Prolay Das, Manas Ranjan Dikhit, Pradeep Das

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ashish KumarDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Ritesh TiwariDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Shobha KumariDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Ravi RanjanDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Vikash KumarDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Sonali VedikaDepartment of Biochemistry, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Kumar AbhishekDepartment of Health Research, MRHRU -ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Prolay DasDepartment of Chemistry, Indian Institute of Technology, Patna, India.
Manas Ranjan DikhitDepartment of Bioinformatics, ICMR- Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Pradeep DasDepartment of Molecular Parasitology, ICMR- National Institute for Research in Bacterial Infections, Kolkata, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aimed to develop a novel nanotherapeutic approach by combining an interleukin-10 (IL-10) peptide antagonist with amphotericin B (AmB) to enhance antileishmanial efficacy while reducing cytotoxicity. MATERIALS AND

methodsA peptide antagonist targeting IL-10, identified via

resultsThe nanoformulation significantly reduced parasite burden and improved amastigote clearance, as confirmed by real-time PCR. Cytokine profiling revealed elevated IL-12 and other protective cytokines, indicating enhanced immune modulation. Hematological, biochemical, and splenomegaly analyses demonstrated improved safety and therapeutic efficacy compared to AmB alone.

conclusionThe IL-10 antagonist - AmB nanoformulation represents a promising immunomodulatory therapeutic strategy for leishmaniasis. Its enhanced efficacy and safety highlight its potential for application, particularly in immunocompromised patients.

Indexed as

Amphotericin BAntiprotozoal AgentsCyclodextrinsInterleukin-10LeishmaniasisNanoparticlesPeptidesAnimalsHumansMiceMice, Inbred BALB CAmphotericin BAntiprotozoal AgentsCyclodextrinsInterleukin-10Peptidesamphotericin Banti IL-10 dictionary peptidein-vivonanoparticleVisceral leishmaniasis

Identifiers

PMID40878891
PMCPMC12505504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.